Business
Scholar Rock to Present at Upcoming Healthcare Conferences in June
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in
About this update from Scholar Rock Holding Corporation
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nScholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences:\n\n\nJefferies Virtual Healthcare Conference on Wednesday, June 2nd, 2021 at 11:00 a.m. ET.\n\n\nGoldman Sachs Annual Global Healthcare Conference on Wednesday, June 9th, 2021 at 2:10 p.m. ET.\n\n\nBMO Biopharma Day: Rare Disease Panel, Central Nervous System on Tuesday, June 22nd, 2021 at 10:30 a.m. ET.\n\n\nA live webcast of presentations at the Jefferies and Goldman Sachs conferences may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.\n\nAbout Scholar Rock\n\nScholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit https://scholarrock.com/ or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/).\n\nScholar Rock® is a registered trademark of Scholar Rock, Inc.\nView source version on businesswire.com: https://www.businesswire.com/news/home/2021052700518...